---
category: news
title: "Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines"
excerpt: "Collaborative efforts aim to accelerate drug discovery and improve clinical success Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection Research will be focused on up to 15 novel small molecule candidates across oncology and immunology Exscientia will receive an upfront cash payment of $100 million with the potential of $5."
publishedDateTime: 2022-01-07T06:02:00Z
originalUrl: "https://apnews.com/press-release/GlobeNewswire/coronavirus-pandemic-business-health-531f9bb727e741335053eb4f43091797"
webUrl: "https://apnews.com/press-release/GlobeNewswire/coronavirus-pandemic-business-health-531f9bb727e741335053eb4f43091797"
type: article
quality: 8
heat: -1
published: false

provider:
  name: Associated Press
  domain: apnews.com

topics:
  - AI

images:
  - url: "https://apnews.com/images/PaidContent3.png"
    width: 700
    height: 450
    isCached: true

related:
  - title: "Sanofi (SNY) Inks Deal to Develop AI-Driven Precision Medicines"
    excerpt: "Sanofi (SNY) signs a collaboration agreement with Exscientia to develop precision-engineered medicines in oncology and immunology using the latter's AI-driven platform."
    publishedDateTime: 2022-01-10T17:01:00Z
    webUrl: "https://www.entrepreneur.com/article/412358"
    type: article
    provider:
      name: Entrepreneur
      domain: entrepreneur.com
    quality: 67
    images:
      - url: "https://assets.entrepreneur.com/providers/zacks/hero-image-zacks-412358.jpeg"
        width: 635
        height: 400
        isCached: true
  - title: "Sanofi partners with AI firm Exscientia to develop up to 15 new drugs"
    excerpt: "French drugmaker Sanofi SA will partner with British AI firm Exscientia Plc to develop up to 15 drug candidates across oncology and immunology, in a deal worth up to US$5.2 billion in milestone payments,"
    publishedDateTime: 2022-01-07T18:59:00Z
    webUrl: "https://www.channelnewsasia.com/business/sanofi-partners-ai-firm-exscientia-develop-15-new-drugs-2420736"
    type: article
    provider:
      name: Channel NewsAsia Singapore
      domain: channelnewsasia.com
    quality: 37
    images:
      - url: "https://onecms-res.cloudinary.com/image/upload/s--ULGSC9r3--/fl_relative%2Cg_south_east%2Cl_one-cms:core:watermark:reuters%2Cw_0.1/f_auto%2Cq_auto/c_fill%2Cg_auto%2Ch_676%2Cw_1200/v1/one-cms/core/2022-01-07t065402z_3_lynxmpei0605t_rtroptp_3_sanofi-results.jpg?itok=QpDT4toX"
        width: 1200
        height: 676
        isCached: true
  - title: "Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia"
    excerpt: "As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to develop oncology and immunology treatments. According to the deal ..."
    publishedDateTime: 2022-01-11T15:17:00Z
    webUrl: "https://www.labiotech.eu/trends-news/exscientia-sanofi-ai/"
    type: article
    provider:
      name: the Top 10
      domain: labiotech.eu
    quality: 37
    images:
      - url: "https://www.labiotech.eu/wp-content/uploads/2022/01/exscientia-ai-sanofi-drug-discovery.jpg"
        width: 1024
        height: 536
        isCached: true

secured: "4qX7UCHncy5UbUEvYLssX4RRkREmAzGPphH5om51N9T4+TbNJEvH58cJRPVFHAWLvsMCzI7QI0OedZ9L2bWbXvcYW3xozk4BPkn8CL9XVyQd8YWLAzBxHg7ncTbgImMRw3v9Ark+DvJIdeOPseLfnDt0dwY8hRZbQyomgKX8bRbEWcF7yLnDrpZiBmkMf8YHM4hDwg9JETEr0LUiKjDpIBo6qFPrTQ7KlrymptA2LIyoc96g9o8JPT8ELfKQbtAUdA6L28Sz46X7iaTg0HFX0YWPiFA6FGlwMjNamWcLjs2AjQDVUWpvaPcKt3O220ETAOf0TvVjy/LW6p7mywHihTaPucMYcz9yuPy8K02LuZA=;7HhfZxShF+n8RXoVgFG+3A=="
---

